# Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

> **NCT00886990** · — · COMPLETED · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 240 (actual)

## Conditions studied

- HIV Infection
- HIV Infections

## Interventions

- **DRUG:** ritonavir-boosted PI-based second line treatments
- **DRUG:** two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir

## Key facts

- **NCT ID:** NCT00886990
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886990, "Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00886990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*